Targeted therapies in solid tumours: results and promises

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Novel therapeutic strategies for solid tumors are emerging.
• Targeted therapies offer potential for reduced toxicity by focusing on specific cancer cell functions.
• Examples include small molecules and monoclonal antibodies targeting proliferation and growth factors.

Purpose of the Study:

• To review the promise and limitations of novel targeted therapies in solid tumor treatment.
• To highlight the gap between preclinical findings and clinical outcomes.
• To emphasize the need for patient selection in targeted cancer therapy.

Main Methods:

• Review of recent advancements in targeted cancer therapy.
• Analysis of preclinical and clinical data for targeted agents.
• Discussion of mechanisms of action for small molecules and monoclonal antibodies.

Main Results:

• Targeted therapies, including small molecules and monoclonal antibodies, demonstrate potential in preclinical models.
• Clinical efficacy has not consistently matched preclinical results.
• Significant inter-patient variability in response is observed.

Conclusions:

• Targeted therapies represent a promising frontier in oncology.
• Clinical application requires careful patient selection to maximize benefits and minimize costs.
• Further research is needed to identify predictive biomarkers for patient stratification.